Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LXEO Lexeo Therapeutics	$4.21 +6.3%	$3.43	$1.45 ▼ $19.50	$131.46M	0.52	531,295 shs	514,448 shs
SIGA Siga Technologies	$6.40 +3.4%	$6.02	$4.95 ▼ $12.83	$442.22M	0.93	724,072 shs	258,843 shs
TRML Tourmaline Bio	$16.94 -0.5%	$16.83	$11.56 ▼ $29.79	$437.17M	2.04	273,497 shs	176,622 shs
ZYBT Zhengye Biotechnology	$7.54 +1.5%	$8.84	$3.50 ▼ $14.30	$350.21M	N/A	521,287 shs	250,931 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LXEO Lexeo Therapeutics	+1.28%	+1.02%	+40.43%	-10.81%	-75.56%
SIGA Siga Technologies	+1.14%	-4.77%	+4.74%	+5.09%	-7.06%
TRML Tourmaline Bio	+2.28%	-10.28%	+11.10%	-0.58%	+11.24%
ZYBT Zhengye Biotechnology	-20.11%	+3.48%	-12.90%	-9.39%	+742,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LXEO Lexeo Therapeutics	1.9517 of 5 stars	3.5	2.0	0.0	0.0	0.0	2.5	0.6
SIGA Siga Technologies	1.7413 of 5 stars	0.0	3.0	0.0	0.0	0.8	0.8	3.1
TRML Tourmaline Bio	2.7986 of 5 stars	3.5	3.0	0.0	0.0	3.1	2.5	0.0
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LXEO Lexeo Therapeutics	3.00	Buy	$16.60	294.30% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A
TRML Tourmaline Bio	3.00	Buy	$49.33	191.22% Upside
ZYBT Zhengye Biotechnology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest LXEO, SIGA, TRML, and ZYBT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00
5/16/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $15.00
5/13/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $20.00
5/5/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/5/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
4/23/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
4/8/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $22.00
4/8/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/26/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
3/25/2025	LXEO Lexeo Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $20.00
3/25/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LXEO Lexeo Therapeutics	$650K	215.03	N/A	N/A	$3.53 per share	1.19
SIGA Siga Technologies	$138.72M	3.30	$0.86 per share	7.40	$3.02 per share	2.12
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$11.71 per share	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LXEO Lexeo Therapeutics	-$98.33M	-$3.30	N/A	N/A	N/A	N/A	-85.86%	-68.48%	8/11/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$0.67	9.55	5.12	N/A	40.30%	25.21%	22.05%	7/30/2025 (Estimated)
TRML Tourmaline Bio	-$73.21M	-$3.21	N/A	N/A	N/A	N/A	-26.75%	-26.11%	8/6/2025 (Estimated)
ZYBT Zhengye Biotechnology	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest LXEO, SIGA, TRML, and ZYBT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	LXEO Lexeo Therapeutics	-$0.80	-$0.99	-$0.19	-$0.99	N/A	N/A
5/8/2025	Q1 2025	SIGA Siga Technologies	N/A	-$0.01	N/A	-$0.01	N/A	$7.04 million
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A
3/24/2025	Q4 2024	LXEO Lexeo Therapeutics	-$0.87	-$0.78	+$0.09	-$0.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Latest LXEO, SIGA, TRML, and ZYBT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/8/2025	SIGA Siga Technologies	special	$0.60		4/29/2025	4/29/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LXEO Lexeo Therapeutics	0.01	3.42	3.42
SIGA Siga Technologies	N/A	8.40	6.28
TRML Tourmaline Bio	N/A	33.87	33.87
ZYBT Zhengye Biotechnology	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LXEO Lexeo Therapeutics	60.67%
SIGA Siga Technologies	55.40%
TRML Tourmaline Bio	91.89%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
LXEO Lexeo Therapeutics	5.30%
SIGA Siga Technologies	1.95%
TRML Tourmaline Bio	13.00%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LXEO Lexeo Therapeutics	58	33.20 million	31.44 million	Not Optionable
SIGA Siga Technologies	40	71.44 million	70.05 million	Optionable
TRML Tourmaline Bio	44	25.68 million	22.35 million	Optionable
ZYBT Zhengye Biotechnology	278	47.17 million	N/A	N/A

LXEO, SIGA, TRML, and ZYBT Headlines

Recent News About These Companies

Zhengye Biotechnology Holding Ltd

June 21 at 7:32 PM | morningstar.com

Zhengye Biotechnology (NASDAQ:ZYBT) Trading Down 6% - Time to Sell?

June 7, 2025 | marketbeat.com

ZYBT Zhengye Biotechnology Holding Limited

May 30, 2025 | seekingalpha.com

Zhengye Biotechnology faces NASDAQ compliance issue

May 24, 2025 | investing.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing Requirements

May 23, 2025 | quiverquant.com

Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F

May 23, 2025 | globenewswire.com

Should We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?

April 7, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Ltd.

April 3, 2025 | wsj.com

Zhengye Biotechnology Holding Limited (ZYBT)

March 27, 2025 | finance.yahoo.com

Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option

January 14, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering

January 8, 2025 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

January 6, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO, SIGA, TRML, and ZYBT Company Descriptions

Lexeo Therapeutics NASDAQ:LXEO

$4.21 +0.25 (+6.31%)

Closing price 04:00 PM Eastern

Extended Trading

$4.03 -0.19 (-4.39%)

As of 07:04 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Siga Technologies NASDAQ:SIGA

$6.40 +0.21 (+3.39%)

Closing price 04:00 PM Eastern

Extended Trading

$6.26 -0.15 (-2.27%)

As of 05:20 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Tourmaline Bio NASDAQ:TRML

$16.94 -0.08 (-0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$16.93 -0.01 (-0.06%)

As of 06:04 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Zhengye Biotechnology NASDAQ:ZYBT

$7.54 +0.11 (+1.48%)

As of 04:00 PM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time